SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Phoenix Financial Ltd. (REGN) drastically reduced its holdings in Regeneron Pharmaceuticals, Inc. by 75.3%, now owning just ...

Vertex Pharmaceuticals (VRTX) wrapped up July with a modest 0.16% uptick, signaling a cautious optimism in the stock market.

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.